for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AMAG Pharmaceuticals, Inc.

AMAG.O

Latest Trade

9.94USD

Change

0.11(+1.07%)

Volume

323,795

Today's Range

9.74

 - 

10.13

52 Week Range

6.81

 - 

19.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.83
Open
9.83
Volume
323,795
3M AVG Volume
18.54
Today's High
10.13
Today's Low
9.74
52 Week High
19.44
52 Week Low
6.81
Shares Out (MIL)
33.92
Market Cap (MIL)
333.39
Forward P/E
-3.70
Dividend (Yield %)
--

Next Event

AMAG Pharmaceuticals Inc at Piper Jaffray Healthcare Conference

Latest Developments

More

Endoceutics - Announce Approval Of Intrarosa By Health Canada For Treatment Of Postmenopausal Vulvovaginal Atrophy

AMAG Pharmaceuticals Reports Q3 Loss Per Share $0.70

AMAG Pharma Announces Settlement Agreement With Caligan Partners LP

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Industry

Biotechnology & Drugs

Contact Info

1100 Winter St

+1.617.4983300

http://www.amagpharma.com/

Executive Leadership

Gino Santini

Independent Chairman of the Board

William K. Heiden

President, Chief Executive Officer, Director

Edward Myles

Chief Financial Officer, Executive Vice President, Treasurer

Elizabeth Bolgiano

Chief Human Resource Officer, Executive Vice President

Joseph D. Vittiglio

Executive Vice President, General Counsel and Corporate Secretary.

Key Stats

3.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.5K

2017

0.6K

2018

0.5K

2019(E)

0.3K
EPS (USD)

2016

6.070

2017

-5.710

2018

-4.920

2019(E)

-2.656
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.02
Price To Book (MRQ)
0.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
56.83
LT Debt To Equity (MRQ)
56.83
Return on Investment (TTM)
-32.19
Return on Equity (TTM)
-26.33

Latest News

Latest News

Amag settles with activist Caligan, adds two board directors

Amag Pharmaceuticals Inc <AMAG.O>, whose shares have tumbled more than 45% in the past year, on Tuesday agreed to add two directors proposed by Caligan Partners after the hedge fund pressured the drugmaker to conduct a strategic business review.

Amag appoints activist investor Caligan's nominees to board

Amag Pharmaceuticals Inc said on Tuesday it settled with activist investor Caligan Partners LP and appointed two of the hedge fund's nominees to its board.

Camber Capital to discuss Amag's board composition with shareholders

Camber Capital Management on Friday unveiled a stake of about 13% in Amag Pharmaceuticals Inc <AMAG.O> and said it intends to discuss the drugmaker's board composition with shareholders, weeks after an activist investor called for a board shake-up.

Camber Capital says Amag Pharma's shares undervalued, seeks changes

Camber Capital Management said on Friday the shares of Amag Pharmaceuticals Inc were undervalued and that it intends to discuss the composition of the company's board of directors with other shareholders.

Amag's female libido injectable therapy to sell at $899

Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).

Amag's female libido injectable therapy to sell at $899

Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for the condition.

FDA approves drug for loss of sexual desire in women

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals' drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as "female Viagra".

FDA approves drug for loss of female sexual desire

The U.S. Food and Drug Administration on Friday approved Palatin Technologies Inc and Amag Pharmaceuticals Inc's drug to restore sexual desire in premenopausal women, Amag said.

BRIEF-AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59

* AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RAISES FULL YEAR FINANCIAL GUIDANCE

BRIEF-AMAG Pharmaceuticals Appoints J. Alan Butcher As Executive Vice President

* AMAG PHARMACEUTICALS APPOINTS J. ALAN BUTCHER AS EXECUTIVE VICE PRESIDENT AND CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide

* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:

BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal

* AMAG PHARMACEUTICALS - CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION

BRIEF-AMAG Reports Q4 Earnings Of $0.10 Per Share

* TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION

BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN

BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEME® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:

BRIEF-AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln

* AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE

Around 6,000 Swiss VW owners seek damages in emissions scandal

Swiss consumer protection organisation SKS has filed a claim on behalf of some 6,000 car owners seeking damages from Volkswagen AG <VOWG_p.DE> and Swiss car dealer AMAG related to the "Dieselgate" emissions scandal.

BRIEF-New Patent Issued To Amag Pharmaceuticals Entitled "Methods Of Reducing Risk Of Preterm Birth"

* NEW PATENT ISSUED TO AMAG PHARMACEUTICALS ENTITLED "METHODS OF REDUCING RISK OF PRETERM BIRTH" Source text for Eikon: Further company coverage:

BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31

* Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up